Large pharmaceutical firms sharpening drug development strategy

摘要

Large pharmaceutical firms, under pressure to bring new medicines to market faster, have been getting more drug candidates into development in recent years and have become more aggressive in terminating unpromising candidates, according to a study recently completed by the US-based Tufts Center for the Study of Drug Development. One in six self-originated compounds that entered clinical testing at large pharmaceutical companies from 1993 to 2004 was expected to eventually attain marketing approval, the study found.